Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Revenue (2023 - 2025)

Historic Revenue for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to $67.5 million.

  • Iovance Biotherapeutics' Revenue rose 1519.94% to $67.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.4 million, marking a year-over-year increase of 17562.24%. This contributed to the annual value of $164.1 million for FY2024, which is 1369899.07% up from last year.
  • Iovance Biotherapeutics' Revenue amounted to $67.5 million in Q3 2025, which was up 1519.94% from $60.0 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Revenue peaked at $73.7 million during Q4 2024, and registered a low of $238000.0 during Q2 2023.
  • Its 3-year average for Revenue is $34.2 million, with a median of $40.2 million in 2024.
  • Per our database at Business Quant, Iovance Biotherapeutics' Revenue surged by 1518921.16% in 2024 and then surged by 1519.94% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Revenue (Quarter) stood at $482000.0 in 2023, then skyrocketed by 15189.21% to $73.7 million in 2024, then dropped by 8.47% to $67.5 million in 2025.
  • Its Revenue was $67.5 million in Q3 2025, compared to $60.0 million in Q2 2025 and $49.3 million in Q1 2025.